Industry News

• Abbott enhances pharmaceutical pipeline with acquisition of Facet Biotech  Abbott and Facet Biotech announced a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.
  Abbott March 09, 2010  
• Vaccinating children against flu helps protect wider community  Results of a clinical trial conducted in a largely self-contained religious community during the 2008-09 influenza season show that immunizing children against seasonal influenza can significantly protect unvaccinated community members against influenza as well.
  National Institutes of Health March 09, 2010  
• Bristol-Myers Squibb and AstraZeneca announce the commencement of the SAVOR-TIMI 53  BMS and AstraZeneca announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA(TM)(saxagliptin).
  Bristol-Myers Squibb Company March 09, 2010  
• Monsanto to break ground on new breeding station in Mississippi  To better serve the needs of southern farmers, Monsanto plans to open a new corn breeding station in Flora, Mississippi. The $2.4 million facility further boosts the company's investment in the South and is a reflection of Monsanto's commitment to continue delivering new high-performing products.
  Monsanto Company March 09, 2010  
• Sanofi-aventis and Merck to create a global leader in Animal Health  Sanofi-aventis and Merck & Co. announced that sanofi-aventis has exercised its option to combine Merial with Intervet/Schering-Plough, Merck's Animal Health business, to create a global leader in Animal Health.
  Merck & Co., Inc. March 09, 2010  
• Novel gene expression test, PROLARIS(TM), accurately predicts prostate cancer recurrence  Myriad Genetics said data that provides further clinical validation supporting its newest molecular diagnostic product, PROLARIS(TM), was recently presented at the 2010 Genitourinary Cancers Symposium in San Francisco.
  Myriad Genetics, Inc. March 08, 2010  
• Lilly to acquire European rights to Pfizer Animal Health assets  Elanco, the animal health division of Eli Lilly and Company, announced that Lilly has signed an agreement to acquire the European rights to a portfolio of certain Pfizer Animal Health products.
  Eli Lilly and Company March 08, 2010  
• Lexicon announces proposed $95 million common stock offering  Lexicon Pharmaceuticals announced that it is offering to sell, subject to market and other conditions, $95,000,000 of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.
  Lexicon Pharmaceuticals, Inc. March 08, 2010  
• Agilent Technologies' executive vice president and CFO Adrian Dillon to leave company  Agilent Technologies announced that Adrian T. Dillon will resign his position as executive vice president, finance and administration, and CFO, effective April 1. Dillon will become chief financial and administration officer at Skype, based in Luxembourg.
  Agilent Technologies Inc. March 05, 2010  
• Opexa Therapeutics reports year end 2009 financial results  Opexa Therapeutics reported a net loss for the year ended December 31, 2009 of $1,433,922 compared with a net loss for the year ended December 31, 2008 of $11,852,152. Cash and cash equivalents were $8,181,582 as of December 31, 2009 compared to $1,243,187 as of December 31, 2008.
  Opexa Therapeutics, Inc. March 05, 2010  

   (next 10 articles)